PT101731A - Processo para a preparacao de composicoes farmaceuticas que contem moleculas de adesao intercelular um seu derivado funcional ou anticorpos ou fragmentos de anticorpos capazes de ligacao a estas moleculas em conjunto com um produto imunossupressivo - Google Patents

Processo para a preparacao de composicoes farmaceuticas que contem moleculas de adesao intercelular um seu derivado funcional ou anticorpos ou fragmentos de anticorpos capazes de ligacao a estas moleculas em conjunto com um produto imunossupressivo Download PDF

Info

Publication number
PT101731A
PT101731A PT101731A PT10173195A PT101731A PT 101731 A PT101731 A PT 101731A PT 101731 A PT101731 A PT 101731A PT 10173195 A PT10173195 A PT 10173195A PT 101731 A PT101731 A PT 101731A
Authority
PT
Portugal
Prior art keywords
molecules
antibodies
immunosuppressive
fragments
lighting
Prior art date
Application number
PT101731A
Other languages
English (en)
Other versions
PT101731B (pt
Inventor
Timothy Alan Springer
Michael Loran Dustin
Robert Rothlein
Steven Dean Marlin
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Publication of PT101731A publication Critical patent/PT101731A/pt
Publication of PT101731B publication Critical patent/PT101731B/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PT101731A 1988-09-28 1995-06-27 Processo para a preparacao de composicoes farmaceuticas que contem moleculas de adesao intercelular um seu derivado funcional ou anticorpos ou fragmentos de anticorpos capazes de ligacao a estas moleculas em conjunto com um produto imunossupressivo PT101731B (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25044688A 1988-09-28 1988-09-28
US32448189A 1989-03-16 1989-03-16
US37388289A 1989-06-30 1989-06-30

Publications (2)

Publication Number Publication Date
PT101731A true PT101731A (pt) 1996-04-30
PT101731B PT101731B (pt) 1997-04-30

Family

ID=27400322

Family Applications (2)

Application Number Title Priority Date Filing Date
PT91834A PT91834B (pt) 1988-09-28 1989-09-28 Processo para a preparacao de moleculas de adesao intercelular e de ligantes que promovem a ligacao destas moleculas bem como de agentes terapeuticos e de diagnostico que os contem
PT101731A PT101731B (pt) 1988-09-28 1995-06-27 Processo para a preparacao de composicoes farmaceuticas que contem moleculas de adesao intercelular um seu derivado funcional ou anticorpos ou fragmentos de anticorpos capazes de ligacao a estas moleculas em conjunto com um produto imunossupressivo

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT91834A PT91834B (pt) 1988-09-28 1989-09-28 Processo para a preparacao de moleculas de adesao intercelular e de ligantes que promovem a ligacao destas moleculas bem como de agentes terapeuticos e de diagnostico que os contem

Country Status (10)

Country Link
EP (2) EP0365837B1 (pt)
AT (2) ATE246245T1 (pt)
CA (1) CA1341185C (pt)
DE (2) DE68929477T2 (pt)
ES (2) ES2077572T3 (pt)
GR (1) GR3017959T3 (pt)
IE (1) IE69975B1 (pt)
MX (1) MX9203212A (pt)
NZ (1) NZ230775A (pt)
PT (2) PT91834B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA896668B (en) * 1988-09-01 1990-06-27 Molecular Therapeutics Inc A human rhinovirus receptor protein that inhibits virus infectivity
EP0362531B1 (en) 1988-09-01 1999-11-10 Bayer Corporation A human rhinovirus receptor protein that inhibits virus infectivity
US6514936B1 (en) 1988-09-01 2003-02-04 Bayer Corporation Antiviral methods using human rhinovirus receptor (ICAM-1)
US6051231A (en) * 1988-09-01 2000-04-18 Bayer Corporation Antiviral methods and prepations
US6143298A (en) * 1988-09-01 2000-11-07 Bayer Corporation Soluble truncated forms of ICAM-1
CA2008368C (en) * 1989-01-24 2003-04-08 Jeffrey Greve Soluble molecule related to but distinct from icam-1
US5776775A (en) * 1989-02-21 1998-07-07 Dana-Farber Cancer Institute Anti-LAM 1-3 antibody and hybridoma
ES2095876T3 (es) 1989-06-02 1997-03-01 Univ Johns Hopkins Med Anticuerpos monoclonales contra la cadena beta de receptores de adhesion de leucocitos; procedimiento de produccion de estos anticuerpos y utilizacion
DK0468257T3 (da) * 1990-07-20 2000-03-27 Bayer Ag Multimer form af human rhinovirusreceptorprotein
US5871733A (en) * 1990-07-20 1999-02-16 Bayer Corporation Multimeric forms of human rhinovirus receptor protein
US5686581A (en) * 1990-07-20 1997-11-11 Bayer Corporation Multimeric form of human rhinovirus receptor protein
US6107461A (en) * 1990-07-20 2000-08-22 Bayer Corporation Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
US5288854A (en) * 1990-11-28 1994-02-22 Center For Blood Research, Inc. Functional derivatives of ICAM-1 which are substantially capable of binding to LFA-1 but are substantially incapable of binding to MAC-1
US5709859A (en) * 1991-01-24 1998-01-20 Bristol-Myers Squibb Company Mixed specificity fusion proteins
CA2120500A1 (en) * 1991-10-01 1993-04-15 Mitsuaki Isobe Preventing allograft rejection with antibodies to adhesion molecules
US5861151A (en) * 1991-12-20 1999-01-19 Bristol-Myers Squibb Co Soluble fusion molecules with binding specificity for cell adhesion molecules
EP0604624A4 (en) * 1992-06-22 1997-03-12 Miles Inc MULTIMERE FORMS OF HUMAN RHINOVIRUS RECEPTOR PROTEIN.
FR2756735B1 (fr) * 1996-12-11 1999-02-26 Thorel Jean Noel Agent d'inhibition de l'expression de la proteine d'adherence icam-1 et compositions cosmetiques et pharmaceutiques le contenant
WO1999022765A1 (en) * 1997-10-30 1999-05-14 Brigham And Women's Hospital Control of lymphocyte localization by leep-cam activity
US20030035798A1 (en) 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
CH694344A5 (de) 2000-09-29 2004-11-30 Pesola Praez Swaagen Ag Federwaage.
CA2454358A1 (en) 2001-07-19 2003-07-31 Perlan Therapeutics, Inc. Multimeric proteins and methods of making and using same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3854536T2 (de) * 1987-05-04 1996-03-07 Dana Farber Cancer Inst Inc Interzellulare Adhäsions-Moleküle und deren Bindungsliganden.
CA1341055C (en) * 1987-12-08 2000-07-18 Alan Mcclelland Transfectant cell lines which express the major human rhinovirus receptor

Also Published As

Publication number Publication date
EP0606518A1 (en) 1994-07-20
NZ230775A (en) 1995-03-28
PT91834B (pt) 1996-08-30
EP0365837A3 (en) 1991-01-09
EP0606518B1 (en) 2003-07-30
DE68923675D1 (de) 1995-09-07
GR3017959T3 (en) 1996-02-29
HK1003105A1 (en) 1998-10-09
EP0365837B1 (en) 1995-08-02
CA1341185C (en) 2001-02-20
DE68929477T2 (de) 2004-06-03
EP0365837A2 (en) 1990-05-02
ATE125708T1 (de) 1995-08-15
DE68923675T2 (de) 1996-02-15
ATE246245T1 (de) 2003-08-15
PT101731B (pt) 1997-04-30
IE893089L (en) 1990-03-28
IE69975B1 (en) 1996-10-16
ES2201052T3 (es) 2004-03-16
DE68929477D1 (de) 2003-09-04
MX9203212A (es) 1992-07-01
PT91834A (pt) 1990-03-30
ES2077572T3 (es) 1995-12-01

Similar Documents

Publication Publication Date Title
PT101731A (pt) Processo para a preparacao de composicoes farmaceuticas que contem moleculas de adesao intercelular um seu derivado funcional ou anticorpos ou fragmentos de anticorpos capazes de ligacao a estas moleculas em conjunto com um produto imunossupressivo
IL86246A0 (en) Intercellular adhesion molecules and functional derivatives thereof,their production and antibodies against thereto
FI901170A0 (fi) Intercellulaer adhesionmolekyl-2 och dess bindeligander.
FI893916A0 (fi) Alfa-subenhet av lfa-1 -leukocytadhesionsreceptor.
EP0364690A3 (en) The alpha-subunit of the mac-1 leukocyte adhesion receptor
BR8301899A (pt) Processo para regulacao do peso molecular de alto cis-1,4-polibutadieno
ES2027325T3 (es) Ultrafiltracion de afinidad con flujo tangencial.
ATE144727T1 (de) Polysaccharid-trenngele und gelsysteme für elektrophorese unter verwendung von sammelgel
ES2141169T3 (es) Proceso para preparar elementos de ensayo.
BR8800406A (pt) Solucoes solidas de pirrolo-(3,4-c)-pirrois e quinacridonas,processo para tingir material organico e material organico de alto peso molecular
DE69328779D1 (de) Benzodiazepin-derivate sowie deren konjugate mit proteinen und polypeptiden
AU5326198A (en) Synthetic biepitope compounds which can be used as standards in the biological assays of troponin I
NO902311L (no) Intracellulaere adhesjonsmolekyler og deres bindingsligander.

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 19960122

MM4A Annulment/lapse due to non-payment of fees, searched and examined patent

Free format text: MAXIMUM VALIDITY LIMIT REACHED

Effective date: 20150629